Dashboard
1
High Management Efficiency with a high ROE of 72.09%
2
Company has a low Debt to Equity ratio (avg) at times
3
Healthy long term growth as Net Sales has grown by an annual rate of 4.94%
4
Flat results in Dec 24
5
With ROE of 70.80%, it has a fair valuation with a 11.34 Price to Book Value
6
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.55%
0%
-27.55%
6 Months
-36.61%
0%
-36.61%
1 Year
-51.37%
0%
-51.37%
2 Years
-56.17%
0%
-56.17%
3 Years
-51.9%
0%
-51.9%
4 Years
-47.01%
0%
-47.01%
5 Years
-56.01%
0%
-56.01%
Bioventix Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.94%
EBIT Growth (5y)
4.20%
EBIT to Interest (avg)
9.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.09
Tax Ratio
23.35%
Dividend Payout Ratio
103.26%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
176.36%
ROE (avg)
72.09%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
11.34
EV to EBIT
11.91
EV to EBITDA
11.78
EV to Capital Employed
20.00
EV to Sales
8.98
PEG Ratio
NA
Dividend Yield
640.82%
ROCE (Latest)
167.96%
ROE (Latest)
70.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
12.80
11.70
9.40%
Operating Profit (PBDIT) excl Other Income
10.20
9.30
9.68%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
8.40
7.70
9.09%
Operating Profit Margin (Excl OI)
783.80%
781.50%
0.23%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is 9.40% vs 7.34% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is 9.09% vs 14.93% in Jun 2022
About Bioventix Plc 
Bioventix Plc
Miscellaneous
Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.
Company Coordinates 
Company Details
7 Romans Business Park, East Street , FARNHAM None : GU9 7SX
Registrar Details






